Researchers from @IMBatUQ / @uq_news, highlighted the association of a molecular target known as protease-activated receptor 2 with women’s cancers, such as such as breast, uterine, ovarian, endometrial, and cervical cancers. Read the article here:

Researchers from @OHSUNews show that while ABL inhibitors such as ponatinib and bosutinib do modulate hemostasis, highly specific new-generation ABL inhibitors, including first-in-class therapeutics, do the article here:

ASPET’s JPET and @PhRMAFoundation are partnering on a Challenge Award competition—a prize of $5,000—to the first author of up to five winning papers! Submit your papers on the #pharmacology of next generation therapeutics by July 1, 2025. 🔗Learn more:

Sejal Sharma, a postdoctoral research scholar at @uw_pharmacy, is the January 2025 Highlighted Trainee Author for JPET. He hopes that his research will contribute to major discoveries in transporter science. Read his work here:

ASPET’s JPET and @PhRMAFoundation are partnering on a Challenge Award competition—a prize of $5,000—to the first author of up to five winning papers! Submit your papers on the #pharmacology of next generation therapeutics by July 1, 2025. 🔗Learn more:

Big news! ASPET's journals are now live on the @ElsevierConnect platform! This partnership will: 🔬 Expand the journals’ global reach 🔬 Increase the usage of innovative technologies 🔬 Provide more opportunities to share cutting-edge science Learn more:

Researchers utilized the large data set of somatic mutations in cancer and the Cancer-Related Analysis of Variants Toolkit, coupled with molecular modeling and docking to screen for mutations in a drug-metabolizing enzyme. Read more here:

A group from the University of Colorado Anschutz Medical Campus reviewed the current state of clinical measurement of early cisplatin toxicity and surmised that using urinary biomarkers will improve early detection of cisplatin toxicity. Read more here:

A group from @uarizona demonstrate that the mouse transporter Oat5 acts similarly to the human drug transporter Oat4. Their data support using mice as a model system and examining mouse Oat5 as a physiological mirror of what would occur in humans. Read it:

The December 2024 Highlighted Trainee Author for JPET is Kennedy Kuchinski, a first-year PhD student at @umichmedicine. Her work focuses on how mutations in drug metabolizing enzymes play a role in cancer #pharmacology. Read her work here:

Researchers at Penn State discuss the current understanding of cannabichromene. With the expected rescheduling of cannabis from Schedule I to Schedule III, research can extend to hundreds of unique molecules derived from cannabis. Read it here:

An expert review by researchers at @UW focuses on CBD and endogenous cannabinoids for treating pain. With the expected rescheduling of cannabis from Schedule I to Schedule III, there is hope research will progress for novel pain medications. Read it here:

Researchers tested a contrary idea: can an opioid that has lower efficacy (effect) be effective at preventing pain? They identified two novel opioids that treat pain but lack many of the adverse effects seen with opioids. Read more here:

Experts present a thorough pre-clinical evaluation of a novel drug targeting ALK-5 and preventing epithelial-mesenchymal transition showing a class-leading reduction in adverse effects, paving the way for PF-06952229 to enter clinical trials. Read it here:

Experts from the @Mayo Clinic explain why elimusertib failed when in animals. They found that not enough elimusertib reached its target in the brain, thereby limiting the drugs effect. Read the article here: @JPET_Journal #pharmacology

Activating cannabinoid receptors may present novel treatments for chemotherapy-induced peripheral neuropathy. With CB1, females' pain response returned before males. With CB2 females and males retained alleviation from pain. Read more:

Authors from @NIDAnews discuss funding and research priorities regarding cannabis in light of the expected rescheduling of cannabis from Schedule I to Schedule III will open many more avenues to fund cannabis research. Read more here:

In a #JPET_Journal article, @NIH_NCCIH delineates their priorities for future cannabis research. Due to the rescheduling of cannabis from Schedule I to Schedule III, 2025 will likely be the beginning of greater research into cannabinoids. Read more here:

Learn about the ASPET Editorial Fellowship and the expectations of successful applicants. Hear from JPET editors on participating in editorial board meetings and aspects of the editorial process on JPET manuscripts. Register here: #pharmacology

The November 2024 Highlighted Trainee Author for #JPET_Journal is Olivia Vanegas. Her research centers on cannabinoid #pharmacology and preclinical pain models. Read her work here: